All Stories

  1. Drug enteric metabolism in gut microbiota-brain crosstalk
  2. Synergic microRNAs suppress human glioblastoma progression by modulating clinically relevant targets
  3. Chronic administration of metformin exerts cytostatic and cytotoxic effects via the PP2A-GSK3β-MCL-1 pathway by inhibiting the tmCLIC1 membrane protein in glioblastoma-initiating cells
  4. A floating endometrial organoid model recapitulates epithelial-stromal cell interactions in vitro
  5. Abstract 5584: The critical role of CLIC1 in mediating metformin's antitumoral effects on glioblastoma
  6. Synergic microRNAs suppress human glioblastoma progression by modulating clinically relevant targets
  7. The expression of pro-prion, a transmembrane isoform of the prion protein, leads to the constitutive activation of the canonical Wnt/β-catenin pathway to sustain the stem-like phenotype of human glioblastoma cells
  8. Ruta graveolens, but Not Rutin, Inhibits Survival, Migration, Invasion, and Vasculogenic Mimicry of Glioblastoma Cells
  9. Chemokine signaling in tumors: potential role of CXC chemokines and their receptors as glioblastoma therapeutic targets
  10. Modulating voltage-gated sodium channels to enhance differentiation and sensitize glioblastoma cells to chemotherapy
  11. Human glioblastoma-derived cell membrane nanovesicles: a novel, cell-specific strategy for boron neutron capture therapy of brain tumors
  12. Expression of calpastatin hcast 3-25 and activity of the calpain/calpastatin system in human glioblastoma stem cells: possible involvement of hcast 3-25 in cell differentiation
  13. Abstract 147: Identification of cell sub-populations in Neuroblastoma cell lines with single-cell-sequencing analysis
  14. Development of Biotinylated Liposomes Encapsulating Metformin for Therapeutic Targeting of Inflammation-Based Diseases
  15. Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas
  16. Metformin potentiates immunosuppressant activity and adipogenic differentiation of human umbilical cord-mesenchymal stem cells
  17. Development and validation of a GC-MS method for determination of metformin in normal brain and in glioblastoma tissues
  18. Editorial: “Small molecules targeting transmembrane receptors and ion channels in drug discovery”
  19. Patient's dermal fibroblasts as disease markers for visceral myopathy
  20. Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?
  21. Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity
  22. Abstract 4788: Oxidative stress promotes colorectal cancer aggressiveness through transmembrane chloride intracellular channel 1 (tmCLIC1) antioxidant activity
  23. The Impact of Experimental Conditions on Cell Mechanics as Measured with Nanoindentation
  24. Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment
  25. Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
  26. Cellular Mechanosensitivity: Validation of an Adaptable 3D-Printed Device for Microindentation
  27. Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
  28. Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives
  29. N6-Isopentenyladenosine Hinders the Vasculogenic Mimicry in Human Glioblastoma Cells through Src-120 Catenin Pathway Modulation and RhoA Activity Inhibition
  30. Structure and Properties of Electrochemically Synthesized Silver Nanoparticles in Aqueous Solution by High-Resolution Techniques
  31. Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting
  32. Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice
  33. Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management
  34. An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma
  35. Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
  36. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects
  37. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  38. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
  39. Exosomes and Extracellular Vesicles as Emerging Theranostic Platforms in Cancer Research
  40. Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization
  41. Co-Administration of Fendiline Hydrochloride Enhances Chemotherapeutic Efficacy of Cisplatin in Neuroblastoma Treatment
  42. Extracellular Vesicles Loaded miRNAs as Potential Modulators Shared Between Glioblastoma, and Parkinson’s and Alzheimer’s Diseases
  43. MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment
  44. Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies
  45. Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells
  46. Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells
  47. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
  48. Abstract 2549: Allostatic conditions in human glioblastoma stem cells are maintained with the contribution of CLIC1 membrane protein functional expression
  49. Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells
  50. Proteases Upregulation in Sporadic Alzheimer’s Disease Brain
  51. Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity
  52. Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity
  53. Large expert-curated database for benchmarking document
  54. Mutual Influence of ROS, pH, and CLIC1 Membrane Protein in the Regulation of G1–S Phase Progression in Human Glioblastoma Stem Cells
  55. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
  56. Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability
  57. Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity
  58. Development of an Injectable Slow-Release Metformin Formulation and Evaluation of Its Potential Antitumor Effects
  59. In Silico Identification and Experimental Validation of Novel Anti-Alzheimer’s Multitargeted Ligands from a Marine Source Featuring a “2-Aminoimidazole plus Aromatic Group” Scaffold
  60. Sprouty2 enhances the tumorigenic potential of glioblastoma cells
  61. Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death
  62. In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity
  63. Primary Cultures from Human GH-secreting or Clinically Non-functioning Pituitary Adenomas
  64. Complexity and Selectivity of γ-Secretase Cleavage on Multiple Substrates: Consequences in Alzheimer’s Disease and Cancer
  65. Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors
  66. Abstract 304: CLIC1 membrane insertion is a pivotal regulator of glioblastoma stem cell G1-S transition by promoting an increase of chloride permeability
  67. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells
  68. Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90–231 Neurotoxic Effects in Cerebellar Granule Neurons
  69. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
  70. Does pasireotide directly modulate skeletal muscle metabolism?
  71. A novel splice variant of the protein tyrosine phosphatasePTPRJthat encodes for a soluble protein involved in angiogenesis
  72. The inhibition of 45A ncRNA expression reduces tumor formation, affecting tumor nodules compactness and metastatic potential in neuroblastoma cells
  73. Subventricular zone microenvironment protects glioblastoma cells from radiotherapy cytotoxicity: role of the chemokine CXCL12
  74. Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide
  75. Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells
  76. A critical concentration of N-terminal pyroglutamylated amyloid beta drives the misfolding of Ab1-42 into more toxic aggregates
  77. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma
  78. FGFR4 Polymorphism as Molecular Determinant of the Efficacy of mTOR Inhibitors In GH-Secreting Pituitary Adenomas
  79. Down-regulation of 21A Alu RNA as a tool to boost proliferation maintaining the tissue regeneration potential of progenitor cells
  80. Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas
  81. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors
  82. Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells
  83. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
  84. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells
  85. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
  86. PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs
  87. Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA
  88. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
  89. Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets
  90. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors
  91. Ruta graveolens L. Induces Death of Glioblastoma Cells and Neural Progenitors, but Not of Neurons, via ERK 1/2 and AKT Activation
  92. Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells
  93. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current
  94. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures
  95. Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA
  96. Adiponectin as Novel Regulator of Cell Proliferation in Human Glioblastoma
  97. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment
  98. Antitumoral effects of metformin on cancer stem cells: identification of novel molecular targets
  99. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
  100. Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System
  101. New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells
  102. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity
  103. Minimalist Hybrid Ligand/Receptor-Based Pharmacophore Model for CXCR4 Applied to a Small-Library of Marine Natural Products Led to the Identification of Phidianidine A as a New CXCR4 Ligand Exhibiting Antagonist Activity
  104. A novel snRNA-like transcript affects amyloidogenesis and cell cycle progression through perturbation of Fe65L1 (APBB2) alternative splicing
  105. Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm
  106. Adult Pituitary Stem Cells
  107. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures
  108. Neuroblastoma: Inhibition by Alu-Like RNA
  109. Metformin selectively affects human glioblastoma tumor-initiating cell viability
  110. Differential toxicity, conformation and morphology of typical initial aggregation states of Aβ1-42 and Aβpy3-42 beta-amyloids
  111. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells
  112. Tryptophan hydroxylase 2 (TPH2) in a neuronal cell line: modulation by cell differentiation and NRSF/rest activity
  113. A Novel Collection of snRNA-Like Promoters with Tissue-Specific Transcription Properties
  114. Excitotoxicity Through NMDA Receptors Mediates Cerebellar Granule Neuron Apoptosis Induced by Prion Protein 90-231 Fragment
  115. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms
  116. Role of Prion Protein Aggregation in Neurotoxicity
  117. Calcium Binding Promotes Prion Protein Fragment 90–231 Conformational Change toward a Membrane Destabilizing and Cytotoxic Structure
  118. NDM29, a RNA polymerase III-dependent non coding RNA, promotes amyloidogenic processing of APP and amyloid β secretion
  119. In vitro study of uptake and synthesis of creatine and its precursors by cerebellar granule cells and astrocytes suggests some hypotheses on the physiopathology of the inherited disorders of creatine metabolism
  120. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
  121. Isolation of stem-like cells from spontaneous feline mammary carcinomas: Phenotypic characterization and tumorigenic potential
  122. Abstract 10: Oncogenic variant EGFRvIII defines a hierarchy in glioblastoma and expression is restricted by epigenetic mechanisms despite the presence of gene amplification
  123. CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis
  124. Amyloid-β Protein Precursor Regulates Phosphorylation and Cellular Compartmentalization of Microtubule Associated Protein Tau
  125. Goat anti‐human GM‐CSF recognizes canine GM‐CSF
  126. Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins
  127. Recombinant Human Prion Protein Fragment 90–231, a Useful Model to Study Prion Neurotoxicity
  128. An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in post-mortem Alzheimer's disease brain samples
  129. Neurodegeneration in Alzheimer Disease: Role of Amyloid Precursor Protein and Presenilin 1 Intracellular Signaling
  130. Persistent increase of d-aspartate in d-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay
  131. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets
  132. The pathological prion protein forms ionic conductance in lipid bilayer
  133. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma
  134. The Chemokine SDF1/CXCL12: A Novel Autocrine/Paracrine Factor Involved In Pituitary Adenoma Development
  135. Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature
  136. An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease
  137. Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction
  138. High hydrophobic amino acid exposure is responsible of the neurotoxic effects induced by E200K or D202N disease-related mutations of the human prion protein
  139. 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease
  140. Somatostatin receptor 1,2 and 5 activation leads to C6 glioma growth arrest in vitro and in vivo; analysis of the intracellular pathways involved
  141. Molecular mechanisms mediating the neuroproyective effects of quinacrine and minocycline on cell death induced by the prion protein fragment 90-231 (hPrP90-231)
  142. Adult Pituitary Stem Cells: From Pituitary Plasticity to Adenoma Development
  143. Chemokines and chemokine receptors: New actors in neuroendocrine regulations
  144. Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors
  145. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5
  146. Somatostatin and somatostatin receptors 1, 2 and 5 selective agonists inhibit C6 glioma cell growth in vitro and in vivo: Analysis of activated intracellular pathways
  147. An Alu‐like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells
  148. Efficacy of Novel Acridine Derivatives in the Inhibition of hPrP90-231 Prion Protein Fragment Toxicity
  149. Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation
  150. The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells
  151. Role of Chemokine Network in the Development and Progression of Ovarian Cancer: A Potential Novel Pharmacological Target
  152. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice
  153. Different Response of Human Glioma Tumor-initiating Cells to Epidermal Growth Factor Receptor Kinase Inhibitors
  154. Dual Modulation of ERK1/2 and p38 MAP Kinase Activities Induced by Minocycline Reverses the Neurotoxic Effects of the Prion Protein Fragment 90–231
  155. The Eighth Fibronectin Type III Domain of Protein Tyrosine Phosphatase Receptor J Influences the Formation of Protein Complexes and Cell Localization
  156. Chemokines and pituitary functions
  157. Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferationin Vitrovia a Phosphotyrosine Phosphatase-η-Dependent Inhibition of Extracellularly Regulated Kinase-1/2
  158. Somatostatin inhibits colon cancer cell growth through cyclooxygenase‐2 downregulation
  159. Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas
  160. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
  161. Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases
  162. Chemokines, their Receptors and Significance in Brain Function
  163. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors
  164. 17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment
  165. Protective Effects of Some Creatine Derivatives in Brain Tissue Anoxia
  166. Intracellular accumulation of a mild‐denatured monomer of the human PrP fragment 90–231, as possible mechanism of its neurotoxic effects
  167. Different structural stability and toxicity of PrPARR and PrPARQ sheep prion protein variants
  168. ERK1/2 and p38 MAP kinases control prion protein fragment 90–231‐induced astrocyte proliferation and microglia activation
  169. Amyloid Precursor Protein and Presenilin Involvement in Cell Signaling
  170. Amyloid Precursor Protein and Presenilin1 Interact with the Adaptor GRB2 and Modulate ERK 1,2 Signaling
  171. Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function
  172. Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract
  173. Amino‐Terminally Truncated Prion Protein PrP90‐231 Induces Microglial Activation in Vitro
  174. Amyloid Precursor Protein and Presenilin 1 Interaction Studied by FRET in Human H4 Cells
  175. An Intracellular Multi-Effector Complex Mediates Somatostatin Receptor 1 Activation of Phospho-Tyrosine Phosphatase η
  176. CXCR4 and SDF1 expression in human meningiomas: A proliferative role in tumoral meningothelial cells in vitro1
  177. Amyloid Precursor Protein Modulates ERK‐1 and ‐2 Signaling
  178. CXC Receptor and Chemokine Expression in Human Meningioma
  179. Characterization of the Proapoptotic Intracellular Mechanisms Induced by a Toxic Conformer of the Recombinant Human Prion Protein Fragment 90-231
  180. SDF‐1 Controls Pituitary Cell Proliferation through the Activation of ERK1/2 and the Ca2+‐Dependent, Cytosolic Tyrosine Kinase Pyk2
  181. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds
  182. Expression of CXC chemokine receptors 1–5 and their ligands in human glioma tissues: Role of CXCR4 and SDF1 in glioma cell proliferation and migration
  183. P4-151
  184. P1-420
  185. P1-422
  186. Conformation Dependent Pro-Apoptotic Activity of the Recombinant Human Prion Protein Fragment 90-231
  187. Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression
  188. Chemokine Stromal Cell-Derived Factor 1α Induces Proliferation and Growth Hormone Release in GH4C1 Rat Pituitary Adenoma Cell Line through Multiple Intracellular Signals
  189. Stromal cell-derived factor-1α (SDF-1α/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation
  190. The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue
  191. Somatostatin Receptor Subtype-Dependent Regulation of Nitric Oxide Release: Involvement of Different Intracellular Pathways
  192. Identification of a Conserved N-Capping Box Important for the Structural Autonomy of the Prion α3-Helix: The Disease Associated D202N Mutation Destabilizes the Helical Conformation
  193. The Phosphotyrosine Phosphatase η Mediates Somatostatin Inhibition of Glioma Proliferation via the Dephosphorylation of ERK1/2
  194. P3-380 Neurotoxicity of the recombinant prion protein fragment 90–231 in SH-SY5Y cells is dependent on its conversion in β-structured-isoform
  195. The Expression of the Phosphotyrosine Phosphatase DEP-1/PTPη Dictates the Responsivity of Glioma Cells to Somatostatin Inhibition of Cell Proliferation
  196. Expression of Somatostatin Receptor mRNA in Human Meningiomas and their Implication in in vitro Antiproliferative Activity
  197. Prion Protein Fragment 106–126 Induces a p38 MAP Kinase—Dependent Apoptosis in SH‐SY5Y Neuroblastoma Cells Independently from the Amyloid Fibril Formation
  198. The Tyrosine Phosphatase Shp-2 Mediates Intracellular Signaling Initiated by Ret Mutants
  199. Pyrrolidinedithiocarbamate induces apoptosis in cerebellar granule cells: involvement of AP-1 and MAP kinases
  200. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH‐secreting pituitary adenoma cells in vitro
  201. Chemokines and their receptors in the CNS: expression of CXCL12/SDF-1 and CXCR4 and their role in astrocyte proliferation
  202. Somatostatin Inhibits Tumor Angiogenesis and Growth via Somatostatin Receptor-3-Mediated Regulation of Endothelial Nitric Oxide Synthase and Mitogen-Activated Protein Kinase Activities
  203. Contribution of two conserved glycine residues to fibrillogenesis of the 106–126 prion protein fragment. Evidence that a soluble variant of the 106–126 peptide is neurotoxic
  204. Basic Fibroblast Growth Factor Activates Endothelial Nitric-Oxide Synthase in CHO-K1 Cells via the Activation of Ceramide Synthesis
  205. In vitro effect of human recombinant leptin and expression of leptin receptors on growth hormone‐secreting human pituitary adenomas
  206. Expression in E. coli and purification of recombinant fragments of wild type and mutant human prion protein
  207. p38 MAP Kinase Mediates the Cell Death Induced by PrP106–126 in the SH-SY5Y Neuroblastoma Cells
  208. Inhibition of nuclear factor-κB activation induces apoptosis in cerebellar granule cells
  209. Inhibition of nuclear factor‐κB activation induces apoptosis in cerebellar granule cells
  210. The Activation of the Phosphotyrosine Phosphatase   (r-PTP ) Is Responsible for the Somatostatin Inhibition of PC Cl3 Thyroid Cell Proliferation
  211. Chemokines and Their Receptors in the Central Nervous System
  212. Stromal cell‐derived factor‐1α induces astrocyte proliferation through the activation of extracellular signal‐regulated kinases 1/2 pathway
  213. Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and membrane receptor‐mediated mechanisms
  214. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2
  215. Apoptotic Cell Death and Impairment of L-Type Voltage-Sensitive Calcium Channel Activity in Rat Cerebellar Granule Cells Treated with the Prion Protein Fragment 106–126
  216. Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106–126
  217. Cultured astrocyte proliferation induced by extracellular guanosine involves endogenous adenosine and is raised by the co-presence of microglia
  218. Cultured astrocyte proliferation induced by extracellular guanosine involves endogenous adenosine and is raised by the co-presence of microglia
  219. A novel mechanism for the melatonin inhibition of testosterone secretion by rat Leydig cells: reduction of GnRH-induced increase in cytosolic Ca2+
  220. Glial and Neuronal Cells Express Functional Chemokine Receptor CXCR4 and Its Natural Ligand Stromal Cell‐Derived Factor 1
  221. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro
  222. Expression of Chemokine Receptors in the Rat Braina
  223. Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: Involvement of A2 purinergic receptor subtypes
  224. Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1)
  225. Prion protein fragment 106-126 induces apoptotic cell death and impairment of L-type voltage-sensitive calcium channel activity in the GH3 cell line
  226. Intracellular Signalling Mediating HIV-1 gp120 Neurotoxicity
  227. TGF-?1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death
  228. Oncogene Transformation of PC Cl3 Clonal Thyroid Cell Line Induces an Autonomous Pattern of Proliferation That Correlates with a Loss of Basal and Stimulated Phosphotyrosine Phosphatase Activity
  229. Somatostatin Inhibits Interleukin 6 Release from Rat Cortical Type I Astrocytes via the Inhibition of Adenylyl Cyclase
  230. Intracellular Calcium Rise through L-Type Calcium Channels, as Molecular Mechanism for Prion Protein Fragment 106-126-Induced Astroglial Proliferation
  231. Cyclic 3,5 adenoise monophosphate and cyclosporin A inhibit cellular proliferation and serine/threonine protein phosphatase activity in pituitary cells
  232. Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors
  233. INTRACELLULAR TRANSDUCING MECHANISMS COUPLED TO BRAIN SOMATOSTATIN RECEPTORS
  234. A PRION PROTEIN FRAGMENT MODIFIES PLASMA MEMBRANE VISCOSITY AND INTRACELLULAR. CALCIUM LEVEL
  235. α1B, But Not α1A, Adrenoceptor Activates Calcium Influx through the Stimulation of a Tyrosine Kinase/Phosphotyrosine Phosphatase Pathway, Following Noradrenaline-Induced Emptying of IP3 Sensitive Calcium Stores, in PC C13 Rat Thyroid Cell Line
  236. The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells
  237. The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin- sensitive pathways
  238. Effect of acetyl-?-carnitine treatment on brain adenylate cyclase activity in young and aged rats
  239. Modulation by GTP of Basal and Agonist‐Stimulated Striatal Adenylate Cyclase Activity Following Chronic Blockade of D1 and D2 Dopamine Receptors: Involvement of G Proteins in the Development of Receptor Supersensitivity
  240. Dopamine and somatostatin inhibition of prolactin secretion from MMQ pituitary cells: role of adenosine triphosphate-sensitive potassium channels
  241. Somatostatin receptor gene expression and related transducing mechanisms in MMQ cells, a prolactin secreting cell line
  242. Molecular mechanisms mediating the effects of l-α-glycerylphosphorylcholine, a new cognition-enhancing drug, on behavioral and biochemical parameters in young and aged rats
  243. G Protein Activation of a Hormone-Stimulated Phosphatase in Human Tumor Cells
  244. Interleukin 6 modulation of second messenger systems in anterior pituitary cells
  245. Age-related alterations of somatostatin gene expression in different rat brain areas
  246. Dihydropyridine Modulation of Voltage‐Activated Calcium Channels in PC12 Cells: Effect of Pertussis Toxin Pretreatment
  247. Cytosolic calcium rise induced by maitotoxin in PC12 cells: Effect of omega-conotoxin (GVIA)
  248. Interleukin 1 beta modulation of TRH stimulated prolactin secretion and inositol phosphate production
  249. Interaction between immune and neuroendocrine systems: interleukin 1 beta inhibition of prolactin release and intracellular transducing mechanisms
  250. Purinergic modulation of adenylate cyclase activity and prolactin secretion in rat adenohypophysis
  251. Interleukin‐1 Modulation of Anterior Pituitary Function.
  252. Fipexide improvement of cognitive functions in rat: Behavioural and neurochemical studies
  253. Anterior pituitary adenosine receptors, coupled to adenylate cyclase, modulate prolactin release
  254. Dihydropiridine inhibition of k+ and maitotoxin stimulated calcium fluxes in pc12 cells: effect of pertussis toxin
  255. Interleukin 1 beta inhibition of TRH-stimulated prolactin secretion and phosphoinositides metabolism
  256. Interleukin I modulation of anterior pituitary function: Effect on hormone release and second messenger systems
  257. Somatostatin inhibition of adenylate cyclase activity in different brain areas
  258. Role of G-proteins in mediating dihydropyridine receptor coupling with voltage sensitive calcium channels
  259. Steroid modulation of prolactin release from single lactotropes in male and female rats studied by the reverse hemolytic plaque assay
  260. A pertussis toxin sensitive G protein mediates dihydropyridine inhibition of maitotoxin stimulated calcium flux in 235-1 pituitary clone
  261. Dihydroergotoxin interaction with central dopaminergic neurotransmission
  262. Effect of interleukin 1 beta on transducing mechanisms in 235-1 clonal pituitary cells
  263. Effect of interleukin 1 beta on transducing mechanisms in 235-1 clonal pituitary cells
  264. Gonadectomy affects prolactin secretion from male and female rat lactotropes: A reverse hemolytic plaque assay study
  265. Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin
  266. Depletion of brain somatostatin (SRIF) by cysteamine (CSH) induces impairment of cognitive functions in rat: Reversal by administration of exogenous SRIF or its analogue SMS 201-995
  267. Pertussis toxin pretreatment abolishes dihydropyridine inhibition of calcium flux in the 235-1 pituitary cell line
  268. Somatostatin inhibition of anterior pituitary adenylate cyclase activity: different sensitivity between male and female rats
  269. Calmodulin modulates prolactin secretion in vitro: Studies with calmodulin containing liposomes
  270. Molecular Mechanisms Mediating Neuronal Cell Death in Experimental Models of Prion Diseases, in vitro